Public Policy Letters, Statements, Legal Briefs, & Other Responses
-
ACMG Comments to CMS about Proposed Changes to the PFS for CY 2021
-
ACMG-ASHG Joint Congressional Briefing on the Undiagnosed Diseases Network
-
ACMG Letter to Congress Regarding the Advancing Access to Precision Medicine Act
-
ACMG Responds to FDA’s Approval for DTC Testing for Three BRCA Gene Mutations
-
Group Sign-on Letter to Congress Opposing the Preserving Employee Wellness Programs Act (HR 1313)
-
ACMG Comments to EEOC Concerning Proposed Rule Related to the Genetic Information Nondiscrimination Act (GINA)
-
ACMG Comments to OHRP Concerning Proposed Revisions to the Common Rule
-
ACMG Response to Expansion of Direct-to-Consumer Genetic Testing
-
ACMG Letter to Congress Supporting the Accurate Education for Prenatal Screenings Act (HR 3441)
-
ACMG Comments to EEOC Concerning Regulations Under the Americans with Disabilities Act (ADA)